Earnings Call Summary | Celcuity(CELC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Celcuity(CELC.US) Q1 2024 Earnings Conference
The following is a summary of the Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript:
以下是Celcuity Inc.(CELC)2024年第一季度财报电话会议记录的摘要:
Financial Performance:
财务业绩:
Celcuity reported a Q1 2024 net loss of $21.6 million, an increase from its Q1 2023 net loss of $11.9 million.
The per share net loss is reported at $0.64 compared to $0.55 per share in Q1 2023.
Non-GAAP net loss for Q1 2024 was $19.9 million or $0.59 per share as compared to $11.9 million or $0.55 per share in Q1 2023.
Research and development expenses increased to $20.7 million, a significant rise from $11.3 million in Q1 2023.
The company maintains a wealth of $177.7 million in cash, cash equivalents, and short-term investments.
Celcuity报告称,2024年第一季度净亏损为2160万美元,较2023年第一季度的1190万美元净亏损有所增加。
报告的每股净亏损为0.64美元,而2023年第一季度为每股亏损0.55美元。
2024年第一季度的非公认会计准则净亏损为1,990万美元,合每股亏损0.59美元,而2023年第一季度为1190万美元,合每股亏损0.55美元。
研发费用增至2,070万美元,较2023年第一季度的1,130万美元大幅增加。
该公司拥有1.777亿美元的现金、现金等价物和短期投资的财富。
Business Progress:
业务进展:
Progress on the Phase 3 VIKTORIA-1 trial remains steady, with Celcuity accomplishing over 50% patient enrollment.
Celcuity kickstarted a Phase 1b/2 trial, focusing on gedatolisib and darolutamide efficacy in patients with metastatic castration-resistant prostate cancer. The preliminary data is expected in H1 2025.
The company maintains its H2 2024 topline guidance and plans for a commercial launch are underway.
The product development strategy is based on the ESMO guidelines aimed at patient populations with endocrine resistance.
Clinical trial quality control will be maintained through adequate stratification of study arms.
The plan of including patients with diverse durations on preceding endocrine therapies is set.
Full data for the wild type cohort is scheduled for disclosure in December 2024, during the San Antonio Breast Cancer meeting.
VIKTORIA-1 三期试验的进展保持稳定,Celcuity的患者入组率超过50%。
Celcuity启动了一项1b/2期试验,重点研究格达托利西布和达洛他胺对转移性去势抵抗性前列腺癌患者的疗效。初步数据预计将在2025年上半年公布。
该公司维持其2024年下半年的收入指导方针,商业发布计划正在进行中。
产品开发策略基于针对内分泌耐药患者群体的ESMO指南。
将通过对研究组进行适当的分层来维持临床试验质量控制。
已经制定了将不同疗程的患者纳入先前内分泌治疗的计划。
野生型队列的完整数据计划于2024年12月在圣安东尼奥乳腺癌会议期间披露。
More details: Celcuity IR
更多详情: Celcuity IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。